Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944031 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of LY3372689 on the Brain in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03944031 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 17 participants.
The verdict
NCT03944031, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment. Screening must be completed within 28 days prior to enrollment.
Interventions
- DRUG LY3372689
- DIAGNOSTIC_TEST [18F]LSN3316612
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2020-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944031
The ClinicalTrials.gov registry entry for NCT03944031 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY3372689 is the first listed.
NCT03944031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03944031 about?
NCT03944031 is a clinical study titled "A Study of the Effects of LY3372689 on the Brain in Healthy Participants". This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment. Screening must be completed within 28 days prior to enrollment.
What is the current status of trial NCT03944031?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-05-08. Estimated completion is 2020-02-19.
What interventions are being tested in trial NCT03944031?
The interventions under investigation include: LY3372689 (DRUG), [18F]LSN3316612 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03944031?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.